Paulo Caramelli, MD, PhD, Federal University of Minas Gerais, Belo Horizonte, Brazil, discusses the impact that global introduction of disease modifying therapies (DMTs), such as anti-amyloid therapies, may have on the use of symptomatic treatments, such as cholinesterase inhibitors, which are currently the standard of care in Alzheimer’s disease (AD). Dr Caramelli believes that these two distinct classes of drugs are not mutually exclusive and that they may be used synergistically in future to improve patient outcomes. It is important to continue to utilize cholinesterase inhibitors, alongside novel DMTs, due to the plethora of long-term data on their safety and clinical effects. This interview took place at the World Congress of Neurology (WCN) 2023 in Montreal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
